Search Results 31-40 of 26105 for 1-(2-desoxi-2-fluoro-β-D-arabinofuranosil)-uracilo

  1. Academic Enrichments - Mayo Clinic College of Medicine & Science

    Advanced Radiation Oncology. 1-2 weeks, 3-8 weeks | Selective. Students participate in the initial evaluation, treatment planning ...

  2. Publications - Aaron S. Mansfield, M.D. - Mayo Clinic

    2024; 2(1):44-52. Griesinger F, Curigliano G, Subbiah V, Baik CS, Tan DS, Lee DH, Misch D, Garralda E, Kim DW, van ...

  3. Publications - Keith C. Bible, M.D., Ph.D. - Mayo Clinic

    ... 2 trial. Lancet Oncol. 2023 Feb; 24 (2):175-186 ... B, Leoni M, Martell B, Scholz C, Gualberto A. ... 2016 Jan; 26 (1):1-133. View PubMed; Bible KC, Cote ...

  4. Publications - Seth R. Sweetser, M.D. - Mayo Clinic

    Anderson B, Johnson D, Sweetser S. An Unusual ... Sunjaya D, Grieb B, Sweetser S. Error of Omission ... 2015 Jul; 149(1):e1-2. Epub 2015 May 28. View ...

  5. ... 2: missing parenthesis on l(\beta, \omega) Page 134, equation 6.6: "d" should be in the denominator, not the numerator. Two lines below it should be dI^{jj} ...

  6. Untitled

    Page 1. Page 2.

  7. Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor - Mayo Clinic

    ... 1:1:1 ratio to Arms A, B, and C. If concurrent dosing is not tolerated in Cohort 1, new participants will be enrolled in a staggered dosing evaluation: Cohort 2 ...

  8. Michael P. Fautsch, Ph.D. - Mayo Clinic

    2019 Feb 1; 60 (2):779-786. View PubMed; Roy Chowdhury U, Dosa PI, Fautsch MP. ATP sensitive potassium channel openers: A new class of ocular hypotensive ...

  9. Publications - Brian E. Lacy, M.D., Ph.D. - Mayo Clinic

    Bor S, Kalkan IH, Savarino E, Rao S, Tack J, Pasricha J, Cangemi D, Schol J, Karunaratne T, Ghisa M, Ahuja NK, Lacy B. · Lembo AJ, Chey WD, Harris LA, Frazier R, ...

  10. A Study of the Safety and Drug/Body Interactions of BGB-3111 for Patients with B-Cell Lymphoid Malignancies - Mayo Clinic

    A Study of the Safety and Drug/Body Interactions of BGB-3111 for Patients with B-Cell Lymphoid Malignancies · Share · Facebook · Twitter.